Optimizing the production of antibodies

Patent metadata

Field	Value
Publication number	US-2016102149-A1
Application number	US-201514975313-A
Country	US
Kind code	A1
Filing date	Dec 18, 2015
Priority date	Jul 24, 2009
Publication date	Apr 14, 2016
Grant date	—

Abstract

A general method is provided for the production of purified antibodies by separation of an antibody molecule from an antibody variant by chromatographic methods, e.g. to enhance therapeutic efficacy, by for example choosing a specific harvesting time point and/or a specific purification scheme. The current invention thus reports a method for producing an antibody composition comprising an antibody molecule and a variant thereof, comprising the following steps: providing a sample comprising the antibody molecule and a variant thereof, determining the presence of the antibody molecule and/or a variant thereof and/or the ratio of the amount of the antibody molecule or variant thereof to the sum of the amounts of the antibody molecule and the variant thereof, in an aliquot of said sample, determining a subsequent harvesting time point and/or antibody purification scheme on basis of the data obtained before, thereby producing an antibody composition comprising the antibody molecule and a variant thereof.

First claim

1 . A method for producing an antibody composition comprising an antibody molecule and a variant thereof, comprising the following steps:
a) providing a sample comprising the antibody molecule and a variant thereof, b) determining the ratio of the amount of the antibody molecule to the sum of the amounts of the antibody molecule and a variant thereof in said sample by an analytical method performed on an aliquot of said sample, and a step c) comprising:
a1) optionally filtrating and/or centrifuging said sample of step a),
a2) optionally performing an affinity chromatography by applying said further filtrated and/or centrifuged sample of step a1) or said sample of step a), on an affinity chromatography column, optionally washing the column and eluting the antibody from the column,
a3) performing a cation exchange chromatography by loading the sample of step a), al) or eluate of step a2) containing the antibody, optionally after adjusting the pH and/or conductivity, onto a cation exchange chromatography column and optionally washing the column, and
a4) eluting the antibody from the cation exchange chromatography column comprising:
i) first, gradually increasing conductivity and/or pH of the buffer applied to the cation exchange column, and
ii) second, by a step wise increase of conductivity and/or pH of the elution buffer applied to the cation exchange column, wherein

if the ratio of the amount of the antibody molecule to the sum of the amounts of the antibody molecule and a variant thereof determined in step b) is below a threshold ratio selected from the range of 65 to 75%,
or
with a step wise increase of conductivity and/or pH without a gradual increase of conductivity and/or pH of the elution buffer applied to the column, if the ratio of the amount of the antibody molecule to the sum of the amounts of the antibody molecule and a variant thereof determined in step a1) is above a threshold ratio selected from the range of 65 to 75%,
thereby producing the antibody composition comprising the antibody molecule and a variant thereof.

2 . The method according to claim 1 , herein the variant of the antibody molecule is an acidic or basic variant.

3 . The method according to claim 2 , wherein the pI of the antibody molecule differs by 0.1 to 0.5 pI units from the pI of the variant.

4 . The method of claim 1 , wherein in step b) the analytical method is ion-exchange chromatography, EISA, or MALDI-TOF analysis.

5 . The method of claim 1 , wherein said sample in step a) is an eluate of an affinity chromatography step or is a cell culture medium comprising an antibody and a variant thereof free from cells and cellular debris.

6 . The method of claim 1 , wherein step a) of providing the sample further comprises:
i) providing a cell containing a nucleic acid molecule comprising a nucleic acid sequence encoding said antibody molecule, ii) cultivating said cell in a medium for 4-28 days, iii) obtaining a sample from the medium, thereby providing the sample comprising the medium, the cell, the antibody molecule and a variant thereof.

7 . The method according to claim 6 , wherein step b) of claim 1 further consists of
iv) determining the ratio of the amount of the antibody molecule to the sum of the amounts of the antibody molecule and a variant thereof in an aliquot of the sample obtained from the medium in step ii) in claim 6 , by analytical ion exchange chromatography, and
v) optionally repeating steps iii) and iv) until the ratio determined in step iv), is 0-2% above a threshold ratio selected from the range of 65% to 75%, and/or
extrapolating the ratio of the amount of the antibody molecule to the sum of the amounts of the antibody molecule and a variant thereof in the medium for a specific cultivation day D, by calculating that ratio according to the following formula:
R x =R 0 −C× ( D x −D o ), wherein

D 0 is a cultivation day, at which the sample in step c) is obtained,
D x is a cultivation day following D 0 ,
R x is the ratio of the amount of the antibody molecule to the sum of the amount of the antibody molecule and a variant thereof at D x ,
R 0 is the ratio of the amount of the antibody molecule to the sum of the amounts of the antibody molecule and a variant thereof at D o , determined in step iv) and
C is a value in the range 1%/day and 5%/day, and corresponds to the daily percentage alteration of the ratio of the amount of the antibody molecule to the sum of the amounts of the antibody molecule and a variant,

vi) recovering the antibody molecule from the medium when R in the medium is 0-2% above the threshold ratio selected from the range of 65 to 75%, and step a3) in claim 1 comprises
vii) performing a cation exchange chromatography by loading the sample of step vi) containing the antibody, optionally after adjusting the pH and/or conductivity onto a cation exchange chromatography column and optionally washing the column,
viii) eluting the antibody from the cation exchange chromatography column with a step wise increase of conductivity and/or pH without a gradual increase of conductivity and/or of the elution buffer applied to the column,
thereby producing an antibody composition comprising the antibody molecule and a variant thereof.

8 . The method of claim 1 , wherein the threshold ratio is 67.5%.

9 . The method of claim 1 , wherein the ratio of the amount of the antibody molecule to the sum of the amounts of the antibody molecule and a variant thereof in the antibody composition produced is from. 50 to 100%, preferably in the range 60 to 100% and most preferred in the range 65 to 100%.

10 . The method of claim 1 , wherein the yield, that is the ratio of the amount of the antibody molecule and a variant thereof in the antibody composition produced by the cation exchange chromatography performed by a step wise increase of conductivity and/or pH without a gradual increase of conductivity and/or pH of the buffer applied to the column, to the amount of the antibody molecule and a variant thereof in the eluate of step a4) containing the antibody molecule and a variant thereof loaded onto the cation exchange chromatography, is more than 65%, preferably more than 70% and most preferred more than 75%.

11 . The method of claim 1 , characterized in that, if an affinity chromatography step is included, the affinity chromatography is a Protein A, or a Protein G, or metal affinity chromatography.

12 . The method of claim 1 , wherein the antibody is a monoclonal antibody.

13 . The method of claim 12 , wherein the monoclonal antibody is a her2 antibody.

14 . The method of claim 13 , wherein the her2 antibody is trastuzumab.

Assignees

• Hoffmann La Roche

Inventors

• Burg Josef
• Hilger Bernhard
• Kaiser Thorsten
• Kuhne Wolfgang
• Stiens Lars
• Wallerius Claus
• Zettl Frank

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K1/18

  Ion-exchange chromatography · CPC title

• C07K2317/14

  Specific host cells or culture conditions, e.g. components, pH or temperature · CPC title